NZ502993A - Treatment of obesity using hGH 177-191analogues - Google Patents

Treatment of obesity using hGH 177-191analogues

Info

Publication number
NZ502993A
NZ502993A NZ502993A NZ50299398A NZ502993A NZ 502993 A NZ502993 A NZ 502993A NZ 502993 A NZ502993 A NZ 502993A NZ 50299398 A NZ50299398 A NZ 50299398A NZ 502993 A NZ502993 A NZ 502993A
Authority
NZ
New Zealand
Prior art keywords
hgh
growth hormone
cys
val
gly
Prior art date
Application number
NZ502993A
Other languages
English (en)
Inventor
Frank Man-Woon Ng
Woei-Jia Jiang
Original Assignee
Metabolic Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO9001A external-priority patent/AUPO900197A0/en
Priority claimed from AUPP0398A external-priority patent/AUPP039897A0/en
Application filed by Metabolic Pharm Ltd filed Critical Metabolic Pharm Ltd
Publication of NZ502993A publication Critical patent/NZ502993A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Photolithography (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Percussion Or Vibration Massage (AREA)
NZ502993A 1997-09-08 1998-09-04 Treatment of obesity using hGH 177-191analogues NZ502993A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO9001A AUPO900197A0 (en) 1997-09-08 1997-09-08 Treatment of obesity
AUPP0398A AUPP039897A0 (en) 1997-11-13 1997-11-13 Treatment of obesity
PCT/AU1998/000724 WO1999012969A1 (en) 1997-09-08 1998-09-04 Treatment of obesity

Publications (1)

Publication Number Publication Date
NZ502993A true NZ502993A (en) 2002-12-20

Family

ID=25645599

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ502993A NZ502993A (en) 1997-09-08 1998-09-04 Treatment of obesity using hGH 177-191analogues

Country Status (12)

Country Link
US (2) US6737407B1 (enExample)
EP (1) EP1012189B1 (enExample)
JP (1) JP4334761B2 (enExample)
CN (1) CN1195776C (enExample)
AT (1) ATE377026T1 (enExample)
BR (1) BR9811755A (enExample)
CA (1) CA2303395C (enExample)
DE (1) DE69838647T2 (enExample)
ES (1) ES2296342T3 (enExample)
NZ (1) NZ502993A (enExample)
RU (1) RU2223970C2 (enExample)
WO (1) WO1999012969A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ387599A0 (en) 1999-11-05 1999-12-02 Metabolic Pharmaceuticals Limited Product and method for control of obesity
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
GB0315182D0 (en) * 2003-06-28 2003-08-06 Asterion Ltd Cytokine variant polypeptides
WO2005007859A2 (en) * 2003-07-11 2005-01-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP4931802B2 (ja) * 2004-05-04 2012-05-16 メタボリック・ファーマシューティカルズ・リミテッド 骨障害を予防または治療するための方法
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
ES2258923B1 (es) * 2005-02-23 2007-11-01 Universitat De Les Illes Balears Uso de la leptina para la prevencion del exceso de peso corporal y composicion que contiene leptina.
JP2009502976A (ja) * 2005-08-02 2009-01-29 メタボリック・ファーマシューティカルズ・リミテッド 親水性ペプチド鎮痛薬の経口送達のためのペプチドコンジュゲート
WO2007068039A1 (en) * 2005-12-12 2007-06-21 Metabolic Pharmaceuticals Limited Treatment of weight gain in estrogen deficient mammals
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
WO2008098280A1 (en) * 2007-02-16 2008-08-21 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of dicarba bridges in growth hormone peptides
EP2340050A2 (en) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymer conjugates of aod-like peptides
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
CN110448683A (zh) * 2011-12-09 2019-11-15 麦特保利药业有限公司 生长激素片段的用途
CN102827290A (zh) * 2012-09-07 2012-12-19 浙江大学 人血清白蛋白与人生长激素脂肪分解结构域的融合蛋白
GB2507341A (en) * 2012-10-29 2014-04-30 Peter Kenny Fat loss composition comprising a prostaglandin F2 alpha analogue and a fragment of amino acids 176-191 of human growth hormone
WO2019136528A1 (en) * 2018-01-15 2019-07-18 Lateral IP Pty Ltd Peptides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG49718A3 (bg) 1983-07-15 1992-01-15 Bio- Technology General Corp Метод за получаване на полипептид със супероксиддисмутазна активност
US4863901A (en) 1986-01-09 1989-09-05 Brigham & Women's Hospital Use of growth hormone for nitrogen retention under hypocaloric conditions
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU693478B2 (en) * 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity

Also Published As

Publication number Publication date
CA2303395A1 (en) 1999-03-18
US6737407B1 (en) 2004-05-18
DE69838647D1 (de) 2007-12-13
JP2002501004A (ja) 2002-01-15
EP1012189A4 (en) 2004-10-20
CN1275132A (zh) 2000-11-29
EP1012189B1 (en) 2007-10-31
ATE377026T1 (de) 2007-11-15
CN1195776C (zh) 2005-04-06
JP4334761B2 (ja) 2009-09-30
EP1012189A1 (en) 2000-06-28
WO1999012969A1 (en) 1999-03-18
BR9811755A (pt) 2000-08-29
DE69838647T2 (de) 2008-08-28
CA2303395C (en) 2008-12-02
US20040192608A1 (en) 2004-09-30
RU2223970C2 (ru) 2004-02-20
ES2296342T3 (es) 2008-04-16

Similar Documents

Publication Publication Date Title
NZ502993A (en) Treatment of obesity using hGH 177-191analogues
Nagai et al. Bicyclic turned dipeptide (BTD) as a β-turn mimetic; its design, synthesis and incorporation into bioactive peptides
Schally et al. The amino acid sequence of a peptide with growth hormone-releasing activity isolated from porcine hypothalamus
Mor et al. Enter a new post-translational modification: D-amino acids in gene-encoded peptides
DE69129865D1 (de) Osteogene peptide
AU6286986A (en) Peptide analogues of mammalian insulin-like growth factor-1
PT81837A (en) Process for preparing oligopeptides and intermediates therefor
MAITA et al. Complete amino acid sequence of Scytalidium lignicolum acid protease B
Greenberg et al. Mitogenic action of osteogenic growth peptide (OGP) Role of amino and carboxy-terminal regions and charge
ES2015366A6 (es) Procedimientos para producir y modificar polipeptidos inhibidores de elastasa y proteinas fusionadas.
DK365484A (da) Fremgangsmaade til fremstilling af polypeptider med endestillet carboxylsyreamidcarboxy
Mizuno et al. A synthesis of a glycopeptide analogue of eel calcitonin
DavidáPallin Cyclisation of totally unprotected peptides in aqueous solution by oxime formation
NO20012232L (no) Enzymatisk amidering av peptider
ATE290088T1 (de) Verfahren zur spaltung eines chimeren proteins mittels eines 'processing'-enzyms
AU1444699A (en) Single-chain polypeptides comprising troponin i and troponin
ATE124955T1 (de) Substrat-peptide.
Nakagawa et al. Production of human PTH (1-34) via a recombinant DNA technique
GR3018181T3 (en) Peptdidylhydroxylglycine N-C lyase and DNA coding therefor.
ATE25984T1 (de) Pharmakologisch aktive peptide.
DE60234843D1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
ES2053978T3 (es) Enzima alfa-amidante en el c-terminal y procedimiento para su produccion.
NZ508812A (en) Peptides for the prevention or treatment of HIV
CA2282734A1 (en) Aminopeptidase derived from bacillus licheniformis and process for preparation of natural type proteins
TH26711A (th) " สิ่งที่คล้ายกันของปัจจัยหลั่งฮอโมนของการเจริญเติบโต "

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired